Skip to main content
. 2014 Sep 5;9(9):e106816. doi: 10.1371/journal.pone.0106816

Figure 1. Influence of the MMP-9 −1562 C/T polymorphism on clinical events in CAD patients with MetS.

Figure 1

A. Number (%) of Composite clinical endpoints in CAD patients as related to the MMP-9 −1562 C/T polymorphism and MetS +/−. White bars: MetS – (CC n = 63, T-allele n = 18), black bars: MetS + (CC n = 10, T-allele n = 15) p-values refer to risk of endpoints in T-allele carriers as compared to the CC genotype. * adjusted for age and gender. B. Number (%) of Composite clinical endpoints in CAD patients as related to the MMP-9 −1562 C/T polymorphism and number of MetS criteria. White bars: CC genotype, black bars: T-allele. p-values refer to risk of endpoints in T-allele carriers as compared to CC genotype when MetS criteria are categorized into 3 groups; 0 and 1 MetS criteria (CC n = 46, T-allele n = 9), 2 and 3 MetS criteria (CC n = 24, T-allele n = 14), and 4 and 5 Mets criteria (CC n = 3, CT n = 10). * adjusted for age and gender.